CN108452094B - Chuanwang anti-inflammation tablet and preparation process thereof - Google Patents
Chuanwang anti-inflammation tablet and preparation process thereof Download PDFInfo
- Publication number
- CN108452094B CN108452094B CN201810169430.4A CN201810169430A CN108452094B CN 108452094 B CN108452094 B CN 108452094B CN 201810169430 A CN201810169430 A CN 201810169430A CN 108452094 B CN108452094 B CN 108452094B
- Authority
- CN
- China
- Prior art keywords
- parts
- stirring
- wheat bran
- filtrate
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Botany (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a Chuanwang anti-inflammatory tablet and a preparation process thereof, wherein the Chuanwang anti-inflammatory tablet mainly comprises the following components in parts by weight: 6-8 parts of modified wheat bran base material, 4-6 parts of functional nano-carrier, 25-60 parts of traditional Chinese medicine extract, 5-7 parts of dextrin, 6-8 parts of sodium carboxymethyl starch and 1.4-1.6 parts of magnesium stearate; the invention can be quickly disintegrated in vivo to ensure that the effective components are uniformly and slowly released, and has the advantages of higher bioavailability, long drug effect time, high safety factor, low renal toxicity, high stability and small weight difference.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a Chuanwang anti-inflammatory tablet and a preparation process thereof.
Background
The Chuanwang anti-inflammatory tablet has the functions of diminishing inflammation and detoxifying, and is used for treating phlegm-heat cough and asthma, abdominal pain, acute and chronic tonsillitis, faucitis, pneumonia, acute gastroenteritis and acute bacillary dysentery with the symptoms. The anti-inflammatory tablet for treating the diseases of the upper respiratory tract and the lower respiratory tract is prepared from andrographis paniculata and Indian stringbush root, wherein the andrographis paniculata is a main drug in a formula, the contained diterpene lactone component dehydroandrographolide is an effective component of the andrographis paniculata for clearing away heat and toxic materials, diminishing inflammation and relieving pain, resisting bacteria and resisting viruses, and the andrographis paniculata is low in water solubility, so that a solid preparation is mostly adopted, but the solid preparation has large absorption individual difference of the drugs after being taken, has uneven bioavailability and directly influences the exertion of the drug effect, and is very important in order to improve the effective utilization degree of the traditional Chinese medicine components and better exert the drug effect and use the drug auxiliary materials which are even, slow-release and stable, therefore, the.
The invention discloses a Chuanwang anti-inflammatory dispersible tablet and a preparation method thereof, wherein the dispersible tablet is prepared by andrographis paniculata dry paste, wikstroemia indica dry paste, cross-linked polyvinylpyrrolidone, microcrystalline cellulose magnesium stearate and starch, the dry paste is extracted according to a proportion, then the cross-linked polyvinylpyrrolidone, microcrystalline cellulose magnesium stearate and starch are added for uniform mixing, tabletting and drying, and finally the Chuanwang anti-inflammatory dispersible tablet is prepared.
Chinese patent with publication number CN1857522A discloses a preparation and quality control method of Chuanwang anti-inflammatory capsule, which is a medicament prepared by extracting herba Andrographitis and Indian stringbush root and mixing with one or more of methylcellulose, hydroxypropyl cellulose, starch, cross-linked polyvinylpyrrolidone and aluminum hydroxide in different combinations, the product of the invention covers the unpleasant smell of the original medicament and is convenient to take; the bioavailability of the medicine can be improved, and the dosage of the auxiliary materials is reduced; the stability of the medicine is increased; the dosage form of the original variety is enriched, and the requirements of different patients are met; however, the capsule of the invention can be rapidly disintegrated, the effective components can be rapidly dissolved out, and the gastrointestinal tract can be easily stimulated, thereby causing adverse reactions.
The traditional Chinese medicine tablet prepared by extracting effective substances from traditional Chinese medicines is the most common and effective utilization method of the traditional Chinese medicines. The tablets have the advantages of accurate dosage, small volume, convenient taking, storage and transportation and the like, and can be prepared into different types according to different requirements, but the tablets prepared by the prior art have larger weight difference, and the difference greatly influences the quality and the curative effect of the medicine, which is a technical problem which always exists in the field. According to the requirements of Chinese pharmacopoeia on the weight difference of tablets, products with excessive weight difference are unqualified.
Disclosure of Invention
In order to solve the defects of the prior art, the invention discloses a Chuanwang anti-inflammatory tablet and a preparation process thereof, the Chuanwang anti-inflammatory tablet can be quickly disintegrated in vivo, so that the effective components are uniformly and slowly released, and the tablet has the advantages of higher bioavailability, long drug effect time, high safety factor, low nephrotoxicity and small weight difference.
The specific technical scheme of the invention is as follows:
the anti-inflammatory tablet for treating the cold comprises the following components in parts by weight: 6-8 parts of modified wheat bran base material, 4-6 parts of functional nano-carrier, 25-60 parts of traditional Chinese medicine extract, 5-7 parts of dextrin, 6-8 parts of sodium carboxymethyl starch and 1.4-1.6 parts of magnesium stearate, wherein the traditional Chinese medicine extract is prepared from common andrographis herb and Indian stringbush root according to the weight ratio of 1 (0.1-1).
Further, the Chuanwang anti-inflammatory tablet comprises the following components in parts by weight: 7 parts of modified wheat bran base material, 5 parts of functional nano-carrier, 40 parts of traditional Chinese medicine extract, 6 parts of dextrin, 7 parts of sodium carboxymethyl starch and 1.5 parts of magnesium stearate, wherein the traditional Chinese medicine extract is prepared from common andrographis herb and Indian stringbush root according to the weight ratio of 1: 0.7.
Further, the preparation method of the modified wheat bran base material comprises the following steps:
s1, grinding the wheat bran to 2000 meshes, mixing with microcrystalline cellulose and water, heating to 40-50 ℃, and stirring for 20-30min to obtain a mixed solution;
s2, adding an initiator K into the mixed solution2S2O8Heating in water bath, stirring for 50-70min, then dropwise adding pure acrylic acid, and stirring for 2-3h to obtain a reaction solution, wherein the volume of the acrylic acid is 1/2 of the volume of the mixed solution;
s3, cooling the reaction liquid to 70-80 ℃, adding polyethylene glycol-4000, stirring for 50-70min, cooling to room temperature, performing suction filtration, washing with absolute ethyl alcohol until no raw material residue exists, and drying to obtain the catalyst.
Further, in the step S1, the feed-liquid ratio of the wheat bran, the microcrystalline cellulose and the water is 1:0.3-0.5: 10-12.
Further, initiator K in step S22S2O8The weight ratio of the wheat bran to the wheat bran is 0.01-0.015: 1.
Further, in step S3, the volume ratio of polyethylene glycol-4000 to acrylic acid is 0.6-0.8: 1.
Furthermore, the functional nano-carrier consists of organic nano-talcum powder, lecithin and arginine according to the weight ratio of 4-6:2-4: 1.
Further, the traditional Chinese medicine extract is prepared by the following steps:
crushing andrographis paniculata and wikstroemia indica to 50-100 meshes, adding distilled water with 5 times volume, placing the solution in a fermentation tank, adding 3 per mill cellulase and 3 per mill pectinase, fermenting for 2 hours at the temperature of 30-45 ℃ and the pH value of 5.5-6.5, stirring aerobically and filtering to obtain filtrate; adding activated carbon into the obtained filtrate for decolorization and filtering, wherein the adding amount of the activated carbon is 1-2% of the total amount of the filtrate; passing the filtrate through D152 resin column, collecting fluid, pasteurizing, and concentrating the fluid to obtain fluid extract with relative density of 1.00-1.20.
Further, the preparation method of the organic nano talcum powder comprises the following steps: preparing polyvinyl alcohol into a solution with the mass fraction of 0.5%, adding talcum powder after 1h, stirring for 5-7 h at the temperature of 80-90 ℃, centrifuging to remove supernatant, and freeze-drying to obtain the polyvinyl alcohol.
Further, the D152 resin was purchased from southern university resin factories.
Furthermore, the weight ratio of the polyvinyl alcohol to the talcum powder is 0.2-0.4: 1.
The invention also discloses a preparation process of the Chuanwang anti-inflammatory tablet, which comprises the following steps:
A) preparing a traditional Chinese medicine extract:
crushing andrographis paniculata and wikstroemia indica to 50-100 meshes, adding distilled water with 5 times volume, placing the solution in a fermentation tank, adding 3 per mill cellulase and 3 per mill pectinase, fermenting for 2 hours at the temperature of 30-45 ℃ and the pH value of 5.5-6.5, stirring aerobically and filtering to obtain filtrate; adding activated carbon into the obtained filtrate for decolorization and filtering, wherein the adding amount of the activated carbon is 1-2% of the total amount of the filtrate; passing the filtrate through D152 resin column, collecting fluid, pasteurizing, and concentrating the fluid to obtain fluid extract with relative density of 1.00-1.20.
B) Preparing a modified wheat bran base material:
s1, grinding the wheat bran to 2000 meshes, mixing with microcrystalline cellulose and water, heating to 40-50 ℃, and stirring for 20-30min to obtain a mixed solution;
s2, adding an initiator K into the mixed solution2S2O8Heating in water bath, stirring for 50-70min, then dropwise adding pure acrylic acid, and stirring for 2-3h to obtain a reaction solution, wherein the volume of the acrylic acid is 1/2 of the volume of the mixed solution;
s3, cooling the reaction liquid to 70-80 ℃, adding polyethylene glycol-4000, stirring for 50-70min, cooling to room temperature, performing suction filtration, washing with absolute ethyl alcohol until no raw material residue exists, and drying to obtain the catalyst.
C) Mixing the Chinese medicinal extract, functional nano-carrier, modified wheat bran base material, dextrin and sodium carboxymethyl starch uniformly, adding ethanol solution 10 times of the weight of the Chinese medicinal powder, mixing and stirring, drying at 60 deg.C for 50-70min, granulating, adding magnesium stearate, mixing, and tabletting.
The Chuanwang antiphlogistic tablet disclosed by the invention is added with a modified wheat bran base material, and is formed by performing acrylic acid grafting reaction on wheat bran and microcrystalline cellulose under the condition of oxidation initiation and then forming a cross-linked structure with polyethylene glycol, wherein the acrylic acid grafted by the wheat bran can effectively improve the water holding capacity of the wheat bran, the cross-linked structure formed by the reaction of the acrylic acid grafted by the wheat bran and the polyethylene glycol can improve the stability of the tablet, so that active ingredients are uniformly and slowly released, the medicine acts in a human body to cause the in vivo kidney electrolyte disorder and the like to generate urea and creatine, and the modified wheat bran base material can adsorb the urea and creatine caused by the medicine, so that the nephrotoxicity of the medicine is reduced, and the.
The anti-inflammatory tablet is added with a functional nano carrier, and is prepared by mixing organic nano talcum powder, lecithin and arginine, wherein the surface of the organic nano talcum powder is provided with a polyvinyl alcohol film layer, so that the affinity of the carrier is improved, and the contained lecithin and arginine are beneficial to the affinity of the medicine to mucosa, promote the absorption of the medicine, improve the bioavailability of the medicine preparation and have no irritation.
The inventor finds in long-term practice that the traditional Chinese medicine extract prepared by the existing extraction process is easy to have different loading amounts when being prepared into tablets, and finally researches a new extraction process through a great deal of experimental research aiming at the phenomenon.
Compared with the prior art, the invention has the following advantages:
(1) the anti-inflammatory tablet for Chuanwang disclosed by the invention can slowly and uniformly release medicinal components, is high in safety and long in medicinal effect time, and reduces the irritation to intestines and stomach;
(2) the modified wheat bran base material adopted by the Chuanwang anti-inflammatory tablet disclosed by the invention can adsorb urea and creatine, so that the adverse effect of the traditional medicinal preparation on the kidney is reduced;
(3) the Chuanwang anti-inflammatory tablet disclosed by the invention adopts a brand-new extraction process, so that the condition of weight difference of the tablet is greatly reduced, and the tablet makes a remarkable progress compared with the prior art.
Detailed Description
The technical solutions of the present invention will be further described by the following examples, so that those skilled in the art can more understand the technical solutions of the present invention.
Example 1 preparation of modified wheat bran base Material
S1, grinding the wheat bran to 2000 meshes, mixing with microcrystalline cellulose and water, heating to 45 ℃, and stirring for 25min to obtain a mixed solution; wherein the feed-liquid ratio of the wheat bran, the microcrystalline cellulose and the water is 1:0.4g: 11;
s2, adding an initiator K into the mixed solution2S2O8Heating in water bath, stirring for 60min, then dropwise adding pure acrylic acid, and stirring for 2.5h to obtain a reaction solution, wherein the volume of the acrylic acid is 1/2 of the volume of the mixed solution; initiator K2S2O8The weight ratio of the wheat bran to the wheat bran is 0.012: 1;
s3, cooling the reaction liquid to 75 ℃, adding polyethylene glycol-4000, stirring for 60min, cooling to room temperature, performing suction filtration, washing with absolute ethyl alcohol until no raw material residue exists, and drying to obtain the catalyst; wherein, the volume ratio of the polyethylene glycol-4000 to the acrylic acid is 0.7: 1.
EXAMPLE 2 preparation of organic Nano Talc powder
Preparing polyvinyl alcohol into a solution with the mass fraction of 0.5%, adding talcum powder after 1h, stirring for 6 hours at the temperature of 85 ℃, centrifuging to remove supernatant, and freeze-drying to obtain the polyvinyl alcohol/talcum powder/polyvinyl alcohol/talcum powder composite material, wherein the weight ratio of polyvinyl alcohol to talcum powder is 0.3: 1.
Example 3 preparation of herbal extracts
Pulverizing herba Andrographitis and Indian Stringbush to 50-100 mesh, adding 5 times volume of distilled water, placing the solution in a fermentation tank, adding 3 ‰ cellulase and 3 ‰ pectase, fermenting at 35 deg.C with pH of 6.0 for 2 hr, stirring under aerobic condition, and filtering to obtain filtrate; adding activated carbon into the obtained filtrate for decolorization and filtering, wherein the adding amount of the activated carbon is 1.5 percent of the total amount of the filtrate; passing the filtrate through D152 resin column, collecting fluid, pasteurizing, and concentrating the fluid to obtain fluid extract with relative density of 1.20 to obtain Chinese medicinal extract.
The Chuanwang anti-inflammatory tablet of embodiments 4 to 6 of the invention comprises the components and the proportion (parts)
| Example 4 | Example 5 | Example 6 | |
| Example 1 modification Wheat bran base | 7 portions of | 6 portions of | 8 portions of |
| Functional nano carrier Body | 5 portions (organic nano talc powder: lecithin: essence) Amino acid as =5:3: 1) | 4 portions (organic nano talc powder: lecithin: essence) Amino acid as =4:2: 1) | 6 portions (organic nano talc powder: lecithin: essence) Amino acid as =6:4: 1) |
| Chinese medicinal extract | 40 parts (common andrographis herb: brother king =3: 2) | 25 parts (common andrographis herb: brother king =3: 2) | 60 parts (common andrographis herb: brother king =3: 2) |
| Dextrin | 6 portions of | 5 portions of | 7 portions of |
| Carboxymethyl starch Sodium salt | 7 portions of | 6 portions of | 8 portions of |
| Magnesium stearate | 1.5 parts of | 1.4 parts of | 1.6 parts of |
The preparation process comprises the following steps:
mixing the Chinese medicinal extract, functional nano-carrier, modified wheat bran base material, dextrin and sodium carboxymethyl starch uniformly, adding ethanol solution 10 times of the weight of the Chinese medicinal powder, mixing and stirring, drying at 60 deg.C for 50-70min, granulating, adding magnesium stearate, mixing, and tabletting.
Comparative example 1 Chuanwang anti-inflammatory tablet
The difference with example 4 is that the modified bran base was replaced by bran powder having a particle size of 2000 mesh, the remaining parameters refer to example 4.
Comparative example 2 Chuanwang anti-inflammatory tablet
The difference from the embodiment 4 is that the preparation method of the modified wheat bran base material does not add microcrystalline cellulose, and specifically comprises the following steps:
(1) grinding the wheat bran to 2000 meshes, mixing with water, heating to 45 ℃, and stirring for 25min to obtain a mixed solution; wherein the feed-liquid ratio of wheat bran to water is 1g to 11 ml;
(2) adding an initiator K2S2O8 into the mixed solution, heating in water bath, stirring for 60min, then dropwise adding pure acrylic acid, and stirring for 2.5h to obtain a reaction solution, wherein the volume of the acrylic acid is 1/2 of the volume of the mixed solution; the weight ratio of the initiator K2S2O8 to the wheat bran is 0.012: 1;
(3) cooling the reaction liquid to 75 ℃, adding polyethylene glycol-4000, stirring for 60min, then cooling to room temperature, carrying out suction filtration, washing by using absolute ethyl alcohol until no raw material residue exists, and drying to obtain the catalyst; wherein, the volume ratio of the polyethylene glycol-4000 to the acrylic acid is 0.7: 1; the remaining parameters are referred to in example 4.
Comparative example 3 Chuanwang anti-inflammatory tablet
The difference from the embodiment 4 is that the preparation method of the traditional Chinese medicine extract does not adopt enzyme extraction, and specifically comprises the following steps:
pulverizing herba Andrographitis and Indian Stringbush to 50-100 mesh, adding 85% ethanol solution, extracting for three times (2 hr each time) at 40 deg.C, mixing extractive solutions, standing, and filtering, wherein the weight ratio of ethanol solution to herba Andrographitis is 4: 1; adding activated carbon into the obtained filtrate for decolorization and filtering, wherein the adding amount of the activated carbon is 1.5 percent of the total amount of the filtrate; passing the filtrate through D152 resin column, collecting fluid, pasteurizing, and concentrating the fluid to obtain fluid extract with relative density of 1.20 to obtain Chinese medicinal extract. The remaining parameters refer to example 4.
Test example I, in vitro drug Release test
Test subjects: chuanwang anti-inflammatory tablets prepared in examples 4-6 and comparative examples 1-2;
the test method comprises the following steps: placing 1 (0.23 g) Chuanwang anti-inflammatory tablet into simulated body fluid (SBF 9 #) of 37 ℃ and 50ml, performing drug release experiment, changing the liquid once every 6 hours, testing the total amount of andrographolide and dehydroandrographolide contained in the extract before each liquid change, wherein the testing method is high performance liquid chromatography, the detection wavelength is 225nm and 250nm, calculating the drug release amount, each sample is tested for 30 days, and the drug release percentage in different time periods is calculated by taking the total amount of andrographolide and dehydroandrographolide measured in an accumulation mode as a base number, and the specific table 1 shows.
TABLE 1 percentage of drug released at different time periods
| Group of | Example 4 | Example 5 | Example 6 | Comparative example 1 | Comparative example 2 |
| 0-6h | 13.2% | 14.9% | 13.8% | 20.6% | 11.4% |
| 6-12h | 12.8% | 12.5% | 12.6% | 18.7% | 16.7% |
| 12-18h | 12.6% | 12.0% | 12.1% | 17.6% | 14.5% |
| 18-24h | 11.9% | 11.5% | 11.0% | 16.1% | 12.1% |
| 24-30h | 11.8% | 10.8% | 10.6% | 10.8% | 11.1% |
| 30-36h | 11.5% | 10.5% | 10.4% | 7.9% | 10.5% |
| 36-42h | 11.2% | 10.0% | 10.1% | 4.9% | 9.7% |
| 42-48h | 7.8% | 7.8% | 9.6% | 1.2% | 8.8% |
| >48h | 7.2% | 10.0% | 9.8% | 2.2% | 5.2% |
As can be seen from the table 1, the Chuanwang anti-inflammatory tablets prepared in the examples 4 to 6 of the invention have good uniform slow release capability, within 0 to 42 hours, the drug release amount of the drug in each time period is smaller, thereby not only avoiding the gastrointestinal irritation caused by too fast drug release speed, but also making up the poor effect caused by slow drug release speed, while the drug release speed of the comparative example 1 is too fast, and the drug release amount of each time period is too large, thereby causing the drug effect time to be short, while the drug release amount of the comparative example 2 is increased and then reduced, thereby causing the drug release speed to be non-uniform.
Test example two, nephrotoxicity test
Test subjects: chuanwang anti-inflammatory tablets prepared in examples 4-6 and comparative examples 1-2;
test animals: the initial weight of the ordinary male SD rat is 210 +/-10 g, and the total weight is 90, and each group contains 18 rats;
the test method comprises the following steps: 0.80g of Chuanwang anti-inflammatory tablet (equivalent to 10 times of the equivalent dosage of human) is continuously infused into the stomach for 300 days, then the kidney is dissected, and the number of rats with renal tubules undergoing water denaturation and the number of mice with renal tubules undergoing spot necrosis are observed, which is shown in table 2.
TABLE 2 nephrotoxicity parameters
| Group of | Amount of water denaturation | Number of spotty necrosis |
| Example 4 | 3 | 0 |
| Example 5 | 4 | 0 |
| Example 6 | 5 | 0 |
| Comparative example 1 | 8 | 3 |
| Comparative example 2 | 9 | 2 |
It can be seen from table 2 that the anti-inflammatory tablets prepared in examples 4-6 of the present invention can greatly reduce the renal toxicity. Comparative examples 1 and 2 rats had a water deformation amount of renal tubules about 3 times that of example 4, and had different cases of spot necrosis.
Test example three, measurement of filling amount difference test
Test subjects: examples 4-6 and comparative example 3;
loading difference detection test: 20 anti-inflammatory tablets of examples 4 to 6 and comparative example 3 were taken, the total weight was precisely measured, the weight of each tablet was measured, and the weight of each tablet was compared with the average weight, and the results are shown in Table 3.
Table 3 weight difference data
| Example 4 | Example 5 | Example 6 | Comparative example 3 | |
| Number of tablets outside the weight variation limit (+ -7.5%) | 0 | 0 | 0 | 5 |
| Number of tablets exceeding 1 time of the limit of weight difference | 0 | 0 | 0 | 0 |
As can be seen from Table 3, the anti-inflammatory tablets prepared in examples 4 to 6 of the present invention each maintained within the specified weight difference limit, the weight difference between the tablets was smaller, and the weight difference of the tablets obtained in comparative example 3 was more significant when the number of tablets exceeding the weight difference limit (+ -7.5%) reached 5.
The foregoing is a preferred embodiment of the present invention and is not to be construed as limited to the embodiments set forth herein, it being understood that: it will be apparent to those skilled in the art that various modifications and adaptations can be made without departing from the principles of the invention and these are intended to be within the scope of the invention.
Claims (6)
1. The Chuanwang anti-inflammatory tablet is characterized by being prepared from the following components in parts by weight: 6-8 parts of modified wheat bran base material, 4-6 parts of functional nano-carrier, 25-60 parts of traditional Chinese medicine extract, 5-7 parts of dextrin, 6-8 parts of sodium carboxymethyl starch and 1.4-1.6 parts of magnesium stearate, wherein the traditional Chinese medicine extract is prepared from common andrographis herb and Indian stringbush root according to the weight ratio of 1 (0.1-1);
the preparation method of the modified wheat bran base material comprises the following steps:
s1, grinding the wheat bran to 2000 meshes, mixing with microcrystalline cellulose and water, heating to 40-50 ℃, and stirring for 20-30min to obtain a mixed solution;
s2, adding an initiator K into the mixed solution2 S2 O8 Heating in water bath, stirring for 50-70min, then dropwise adding pure acrylic acid, and stirring for 2-3h to obtain a reaction solution, wherein the volume of the acrylic acid is 1/2 of the volume of the mixed solution;
s3, cooling the reaction liquid to 70-80 ℃, adding polyethylene glycol-4000, stirring for 50-70min, cooling to room temperature, performing suction filtration, washing with absolute ethyl alcohol until no raw material residue exists, and drying to obtain the catalyst;
the traditional Chinese medicine extract is prepared by the following steps:
crushing andrographis paniculata and wikstroemia indica to 50-100 meshes, adding distilled water with 5 times volume, placing the solution in a fermentation tank, adding 3 per mill cellulase and 3 per mill pectinase, fermenting for 2 hours at the temperature of 30-45 ℃ and the pH value of 5.5-6.5, stirring aerobically and filtering to obtain filtrate; adding activated carbon into the obtained filtrate for decolorization and filtering, wherein the adding amount of the activated carbon is 1-2% of the total amount of the filtrate; passing the filtrate through D152 resin column, collecting fluid, performing pasteurization, and concentrating the fluid to obtain fluid extract with relative density of 1.00-1.20 to obtain Chinese medicinal extract;
the functional nano-carrier consists of organic nano-talcum powder, lecithin and arginine according to the weight ratio of 4-6:2-4: 1.
2. The anti-inflammatory tablet for the cowherb seed according to claim 1, which is prepared from the following components in parts by weight: 7 parts of modified wheat bran base material, 5 parts of functional nano-carrier, 40 parts of traditional Chinese medicine extract, 6 parts of dextrin, 7 parts of sodium carboxymethyl starch and 1.5 parts of magnesium stearate, wherein the traditional Chinese medicine extract is prepared from common andrographis herb and Indian stringbush root according to the weight ratio of 1: 0.7.
3. The Chuanwang anti-inflammatory tablet of claim 1, wherein in step S1, the feed-liquid ratio of wheat bran, microcrystalline cellulose and water is 1:0.3-0.5: 10-12; the initiator K in the step S22 S2 O8 The weight ratio of the wheat bran to the polyethylene glycol-4000 is 0.01-0.015:1, and the volume ratio of the polyethylene glycol-4000 to the acrylic acid in the step S3 is 0.6-0.8: 1.
4. The anti-inflammatory tablet of queen bee according to claim 1, wherein the preparation method of the organic nano talcum powder comprises the following steps: preparing polyvinyl alcohol into a solution with the mass fraction of 0.5%, adding talcum powder after 1h, stirring for 5-7 h at the temperature of 80-90 ℃, centrifuging to remove supernatant, and freeze-drying to obtain the polyvinyl alcohol.
5. The anti-inflammatory tablet according to claim 4, wherein the weight ratio of polyvinyl alcohol to talc is 0.2-0.4: 1.
6. The preparation process of the anti-inflammatory tablet for the Chuanwang according to any one of the claims 1 to 5, which is characterized by comprising the following steps:
A) preparing a traditional Chinese medicine extract:
crushing andrographis paniculata and wikstroemia indica to 50-100 meshes, adding distilled water with 5 times volume, placing the solution in a fermentation tank, adding 3 per mill cellulase and 3 per mill pectinase, fermenting for 2 hours at the temperature of 30-45 ℃ and the pH value of 5.5-6.5, stirring aerobically and filtering to obtain filtrate; adding activated carbon into the obtained filtrate for decolorization and filtering, wherein the adding amount of the activated carbon is 1-2% of the total amount of the filtrate; passing the filtrate through D152 resin column, collecting fluid, pasteurizing, and concentrating the fluid to obtain fluid extract with relative density of 1.00-1.20 to obtain Chinese medicinal extract;
B) preparing a modified wheat bran base material:
s1, grinding the wheat bran to 2000 meshes, mixing with microcrystalline cellulose and water, heating to 40-50 ℃, and stirring for 20-30min to obtain a mixed solution;
s2, adding an initiator K into the mixed solution2 S2 O8 Heating in water bath, stirring for 50-70min, then dropwise adding pure acrylic acid, and stirring for 2-3h to obtain a reaction solution, wherein the volume of the acrylic acid is 1/2 of the volume of the mixed solution;
s3, cooling the reaction liquid to 70-80 ℃, adding polyethylene glycol-4000, stirring for 50-70min, cooling to room temperature, performing suction filtration, washing with absolute ethyl alcohol until no raw material residue exists, and drying to obtain the catalyst;
C) mixing the Chinese medicinal extract, functional nano-carrier, modified wheat bran base material, dextrin and sodium carboxymethyl starch uniformly, adding ethanol solution 10 times of the weight of the Chinese medicinal powder, mixing and stirring, drying at 60 deg.C for 50-70min, granulating, adding magnesium stearate, mixing, and tabletting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810169430.4A CN108452094B (en) | 2018-02-28 | 2018-02-28 | Chuanwang anti-inflammation tablet and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810169430.4A CN108452094B (en) | 2018-02-28 | 2018-02-28 | Chuanwang anti-inflammation tablet and preparation process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108452094A CN108452094A (en) | 2018-08-28 |
| CN108452094B true CN108452094B (en) | 2021-04-23 |
Family
ID=63217701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810169430.4A Active CN108452094B (en) | 2018-02-28 | 2018-02-28 | Chuanwang anti-inflammation tablet and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108452094B (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105708799A (en) * | 2016-01-27 | 2016-06-29 | 金银秀 | Nano-structural lipid carrier pharmaceutical composition and preparation method thereof |
| CN106950294A (en) * | 2017-02-22 | 2017-07-14 | 江西普正植物药科技协同创新有限公司 | A kind of antiphlogistic Chunwang capsule quality determining method |
-
2018
- 2018-02-28 CN CN201810169430.4A patent/CN108452094B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| "纤维素酶用于中药穿心莲提取的初步研究";马桔云，等;《黑龙江医药》;20000229;第13卷(第1期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108452094A (en) | 2018-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104844723B (en) | A kind of preparation method and application of Herba Dendrobii extract | |
| CN113150867B (en) | Preparation method of ganoderma lucidum extract oil rich in ganoderma lucidum triterpenes | |
| WO2015081703A1 (en) | Solid dispersion containing desmodium styracifolium (osb.) merr. flavonoids, method of preparing same, and use thereof | |
| CN114832022B (en) | Preparation of Phellinus linteus fruiting body phenol active substances and application thereof in regulating intestinal flora and uric acid metabolism | |
| CN102805767B (en) | Heat stranguria removal granule raw material polygonum capitatum extract with anti-gonococcus effect | |
| CN1229324C (en) | Extraction process of tanshin general phenolic acid and its prepn and use | |
| CN108452094B (en) | Chuanwang anti-inflammation tablet and preparation process thereof | |
| CN110664960B (en) | Traditional Chinese medicine composition for gastric mucosa precancerous lesion and preparation method and application thereof | |
| CN101849950A (en) | Application of rotundic acid in preparing blood lipid regulating medicines | |
| WO2024031830A1 (en) | Feng liao chang wei kang tablet and preparation technology therefor | |
| CN101549010B (en) | A preparing method and application of malaytea scurfpea fruit total glycosides extract | |
| CN115554325A (en) | Application of medicine terminalia fruit, extractive or preparation thereof in preparing anti-inflammatory, analgesic or uric acid-reducing medicines | |
| CN103585208A (en) | Preparation method of high-quality andrographolide component | |
| CN102526237A (en) | Medicinal composition for removing advanced oxidation protein final product and application thereof | |
| CN106974917B (en) | Application of exodermis poria triterpene in preparation of medicine for treating nephropathy | |
| CN103566281B (en) | A kind of Traditional Chinese medicine composition with anti-tumor effect and preparation method | |
| CN106074807A (en) | A kind of preparation method of rotor angle predicting | |
| CN101953857A (en) | Compound fermented cordyceps sinensis bacterium powder (paecilomyces hepiali Cs-4 bacterium powder) composite medicine | |
| CN111110825A (en) | Composition for reducing uric acid and preparation method and application thereof | |
| CN100363018C (en) | Honeysuckle flower soft capsule and preparation method thereof | |
| CN115671123B (en) | Application of clematis root saponin in preparation of purine-reducing medicament | |
| CN102488805A (en) | Method for preparing Shenshuaining preparations with polymeric flocculation and precipitation technology | |
| CN114848710B (en) | Preparation and application of compound traditional Chinese medicine composition for treating chronic plasma cell mastitis | |
| CN112353880B (en) | Preparation method of children cold-relieving traditional Chinese medicine | |
| CN114479513B (en) | Preparation method of high-purity high-yield curcumin and application of curcumin in anti-alcohol and liver protection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: No. 188, Longbao Road, Shuangdong street, Luoding City, Yunfu City, Guangdong Province Applicant after: Yili Pharmaceutical (Luoding) Co.,Ltd. Address before: No. 188, Longbao Road, Shuangdong street, Luoding City, Yunfu City, Guangdong Province Applicant before: GUANGDONG YILI LUODING PHARMACEUTICAL Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zeng Sheng Inventor after: Huang Xin Inventor after: Zhang Kun Inventor after: Zhang Yongqian Inventor after: Liang Zhijun Inventor before: Zeng Sheng |